Organovo Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>OH</div>
ONVO -- USA Stock  

USD 13.59  0.34  2.57%

In general, we focus on analyzing Organovo (NASDAQ:ONVO) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Organovo Holdings daily price indicators and compare them against related drivers. Let's try to outline what's happening with Organovo Holdings amid unprecedented political, and economic uncertainty.
Published over a month ago
View all stories for Organovo Holdings | View All Stories
Continue to hold Organovo Holdings (NASDAQ:ONVO)?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Organovo Holdings has an asset utilization ratio of 0.44 percent. This suggests that the company is making $0.00441 for each dollar of assets. An increasing asset utilization means that Organovo Holdings is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Organovo Holdings stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Organovo Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Organovo Holdings based on Organovo Holdings hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Organovo Holdings's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Organovo Holdings's related companies.

Use Technical Analysis to project Organovo expected Price

Organovo Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Organovo Holdings technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Organovo Holdings trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Organovo utilizes its cash?

To perform a cash flow analysis of Organovo Holdings, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Organovo Holdings is receiving and how much cash it distributes out in a given period. The Organovo Holdings cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Organovo Holdings Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (10.46 Million)

Acquisition by Keith Murphy of 65000 shares of Organovo Holdings subject to Rule 16b-3

Legal trades by Organovo Holdings insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Organovo insider trading alert for grant of stock option (right to buy) by Keith Murphy, Executive Chairman, on 11th of December 2020. This event was filed by Organovo Holdings Inc with SEC on 2020-12-11. Statement of changes in beneficial ownership - SEC Form 4. Keith Murphy currently serves as chairman, ceo and president member of audit committee and member of science and technology committee of Organovo Holdings [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

This firm reported the previous year's revenue of 298 K. Net Loss for the year was (17.81 M) with loss before overhead, payroll, taxes, and interest of (3.42 M).

Deferred Revenue Breakdown

Organovo Holdings Deferred Revenue yearly trend continues to be quite stable with very little volatility. Deferred Revenue may rise above about 157 K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Organovo Holdings Deferred Revenue is quite stable at the moment as compared to the past year. The company's current value of Deferred Revenue is estimated at 157,026
20151.11 Million

Will Organovo Holdings latest rise continue?

Latest Jensen Alpha is up to -0.09. Price may slide again. Organovo Holdings exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Organovo Holdings individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Organovo Holdings future systematic risk.

Our Final Perspective on Organovo Holdings

Whereas some other companies under the diagnostics & research industry are still a bit expensive, Organovo Holdings may offer a potential longer-term growth to institutional investors. All things considered, as of the 18th of December 2020, we believe that at this point, Organovo Holdings is relatively risky with high odds of financial distress within the next 2 years. From a slightly different point of view, the entity appears to be overvalued. Our up-to-date 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Organovo Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to